Serena Nik-Zainal, MD, discusses study findings that could change the way treatment strategies for subgroups of patients with triple-negative breast cancer are evaluated.
Researchers report on the BRIGHT AML 1019 Phase III trial.
A new study looked at the characteristics of diagnosed breast cancer cases in San Francisco.
Several clinicopathologic features of HER2-positive breast cancer patients were found to be associated with response to neoadjuvant therapy in a new study.
Researchers explore the predictive capability of EVI1 expression.
CancerNetwork® spoke with Dr. Peter Schmid about the KEYNOTE-522 trial.
TAS-102 improved overall survival, compared with placebo, in patients with metastatic gastric or gastroesophageal junction (GEJ) cancer.
The results showed that even patients with disease that has spread to the brain should be considered for immunotherapy.
One-third of patients with locally advanced non-small cell lung cancer treated with durvalumab developed symptomatic pneumonitis.
The agent has a high affinity and specificity for interleukin-1 beta.